Role of Intrathecal Rituximab and Trastuzumab in the Management of Leptomeningeal Carcinomatosis by Perissinotti, Anthony J. & Reeves, David J.
Butler University
Digital Commons @ Butler University
Scholarship and Professional Work – COPHS College of Pharmacy & Health Sciences
2010
Role of Intrathecal Rituximab and Trastuzumab in
the Management of Leptomeningeal
Carcinomatosis
Anthony J. Perissinotti
David J. Reeves
Butler University, dreeves@butler.edu
Follow this and additional works at: http://digitalcommons.butler.edu/cophs_papers
Part of the Oncology Commons, and the Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the College of Pharmacy & Health Sciences at Digital Commons @ Butler University. It has
been accepted for inclusion in Scholarship and Professional Work – COPHS by an authorized administrator of Digital Commons @ Butler University.
For more information, please contact fgaede@butler.edu.
Recommended Citation
Perissinotti, Anthony J. and Reeves, David J., "Role of Intrathecal Rituximab and Trastuzumab in the Management of Leptomeningeal
Carcinomatosis" (2010). Scholarship and Professional Work – COPHS. Paper 208.
http://digitalcommons.butler.edu/cophs_papers/208
Role of Intrathecal Rituximab and Trastuzumab in the 
Management of Leptomeningeal Carcinomatosis 
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Abstract 
OBJECTIVE: To review evidence for the use of intrathecal rituximab and trastuzumab in the 
management of leptomeningeal carcinomatosis.  
DATA SOURCES: A search of MEDLINE (1966-July 2010) and International Pharmaceutical 
Abstracts (1970-July 2010) was performed using search terms intrathecal, trastuzumab, rituximab, and 
monoclonal antibody. Additionally, American Society of Clinical Oncology, San Antonio Breast 
Conference, American Association for Cancer Research, and American Society of Hematology meeting 
abstracts were searched.  
STUDY SELECTION AND DATA EXTRACTION: Publications were reviewed for inclusion. Those 
reporting use of rituximab and trastuzumab intrathecally are reviewed and include 1 Phase 1 trial, 2 small 
prospective studies, 1 case series, and 15 case reports.  
DATA SYNTHESIS: The treatment of leptomeningeal carcinomatosis is challenging due to the presence 
of the blood-brain barrier. Numerous systemically administered therapies do not readily penetrate into the 
site of leptomeningeal disease and have been ineffective. Intrathecal administration of 2 monoclonal 
antibodies (trastuzumab and rituximab) has been investigated in case reports and case series. 
Additionally, intrathecal rituximab has been investigated in a Phase 1 study. Survival after intrathecal 
trastuzumab ranged from 39 days to greater than 72 months and the drug was well tolerated, with no 
adverse events attributed to it. Doses used in these reports ranged from 5 to 100 mg. Survival after 
intrathecal rituximab ranged from 1.1 weeks to greater than 3.5 years. In the Phase 1 trial, the maximum 
tolerated rituximab dose was 25 mg and 60% of patients responded. Four of the 6 responding patients 
experienced a complete response. Intrathecal rituximab exhibited minor toxicities that resolved quickly 
without long-term effects.  
CONCLUSIONS: Reports suggest that both trastuzumab and rituximab may be utilized intrathecally. 
Patients with refractory leptomeningeal carcinomatosis may benefit from a trial of intrathecal trastuzumab 
or rituximab; however, their use remains investigational, as more data and experience are necessary 
before intrathecal administration can be considered standard.  
 
 
 
 
 
 
Request 
Is there a role for intrathecally administered rituximab and trastuzumab in the treatment of 
leptomeningeal carcinomatosis? 
Response 
BACKGROUND 
Leptomeningeal carcinomatosis, also known as neoplastic meningitis, occurs when malignant cells 
enter the leptomeningeal space via hematogenous dissemination or direct extension.1 The 
malignant cells are spread throughout the neuraxis by the flow of the cerebrospinal fluid (CSF), 
leading to disease throughout the central nervous system (CNS). Leptomeningeal carcinomatosis 
leads to substantial morbidity and mortality, and there are few, if any, effective treatments. 
Fortunately, the incidence of leptomeningeal carcinomatosis remains low, at approximately 5% of 
patients with cancer.1,2 However, the frequency with which this complication is diagnosed is 
believed to be increasing due to greater control of systemic disease, longer survival, and 
improvements in neuroimaging.1,2 This incidence varies among the solid tumors and is most 
common with breast cancer, smallcell lung cancer, and melanoma.2 Lymphoma may also cause 
neoplastic meningitis, termed lymphomatous carcinomatosis. Typically, survival is measured in 
weeks without treatment and approaches 3–6 months with traditional treatments.2 Treatments 
commonly utilized for the management of leptomeningeal carcinomatosis include radiation, 
systemic chemotherapy, and intrathecal chemotherapy. Drugs currently utilized intrathecally 
include cytarabine, liposomal cytarabine, methotrexate, and thiotepa. According to the National 
Comprehensive Cancer Network, patients with leptomeningeal carcinomatosis may be considered 
for either supportive care, fractionated external beam radiation to symptomatic sites, or intrathecal 
chemotherapy.1 Patients with lymphomatous carcinomatosis have additional options, including 
steroid administration and systemic chemotherapy with high-dose methotrexate.1 Despite these 
conventional therapies, response still remains low. 
Due to the presence of the blood—brain and blood—cerebrospinal barriers, it is difficult for 
systemically administered chemotherapy to penetrate into the site of leptomeningeal disease. 
Further hindering penetration of chemotherapy into the CSF are the adverse effects associated with 
the high doses of systemically administered drugs required to achieve adequate CNS 
concentrations. Many agents, including monoclonal antibodies, tend to be large molecules and 
those weighing above 200 kDA have minimal penetration into the CSF. Due to low CNS 
penetration of most chemotherapy, the CNS often acts as a sanctuary site for tumor cells. For these 
reasons the desired route of administration is intrathecal; however, response is generally short lived 
and patients may develop adverse effects such as arachnoiditis from the chemotherapy. 
More recently, intrathecal administration of 2 monoclonal antibodies has been investigated, 
representing a novel and targeted treatment for leptomeningeal carcinomatosis. Intrathecal 
trastuzumab, an anti-human epidermal growth factor receptor (HER2) monoclonal antibody, has 
been utilized and reported in HER2-positive breast cancer. Additionally, intrathecal rituximab, an 
anti-CD20 monoclonal antibody, has been investigated in B-cell lymphoma and leukemia. Though 
much of the data are preliminary, there has been interest in utilizing such novel agents in the 
management of leptomeningeal carcinomatosis.  
Another emerging option for the treatment of HER2-positive breast cancer with leptomeningeal 
carcinomatosis is the oral tyrosine kinase inhibitor lapatinib. It shows promise for leptomeningeal 
carcinomatosis, as it is a small molecule (<1 kDa) able to penetrate the blood-brain barrier. 
However, 2 Phase 2 trials (EGF105084 and NCI-6969) that studied lapatinib monotherapy for 
leptomeningeal carcinomatosis were both terminated prematurely, as they failed to meet their 
primary endpoints.34 The modest effects observed in clinical trials may be attributed to efflux 
transporters that pump the drug out of the CNS. Lapatinib is not discussed in this review.  
LITERATURE REVIEW 
A search of MEDLINE (1966-July 2010) and International Pharmaceutical Abstracts (1970-July 
2010) was performed using the search terms intrathecal, trastuzumab, rituximab, and monoclonal 
antibody. Relevant articles were identified and references of these articles were reviewed for 
additional reports. Meeting abstracts of the American Society of Clinical Oncology, the San 
Antonio Breast Conference, the American Association for Cancer Research, and the American 
Society of Hematology were also searched. Reports most pertinent to the use of intrathecal 
trastuzumab and rituximab are reviewed here.  
HER2-Positive Breast Cancer and Intrathecal Trastuzumab 
Trastuzumab plays a central role in the treatment of HER2-positive breast cancer and has been 
shown to increase survival. Whether due to this increase in survival, the lack of trastuzumab 
penetration into the CNS, or the aggressive natural history of HER2-positive breast cancer, patients 
receiving trastuzumab may have a higher incidence of CNS metastases.5 It has been shown that 
CSF concentrations of trastuzumab are 300- to 400-fold lower than serum concentrations.6,7 These 
concentrations may be increased by inflammation or whole-brain radiation therapy; however, 
concentrations still remain between 1/76 and 1/49 of those in plasma and may not be consistently 
high enough to have a therapeutic effect.7 With the known activity of trastuzumab and difficulty 
in achieving adequate CNS concentrations, intrathecal administration has been considered.  
In a rat model, trastuzumab was administered via direct intracerebral microinfusion or 
intraperitoneally after transplantation of HER2 breast cancer cells into the cerebrum.8 Among rats 
receiving systemic (intraperitoneal) trastuzumab, survival was 26.5 days, while the median 
survival of those receiving intracerebral trastuzumab was 52 days. No toxicity was evident in those 
receiving intracerebral trastuzumab. Another animal model utilizing cynomolgus monkeys 
evaluated the toxicity and pharmacokinetics of intrathecal trastuzumab.9 Doses equated to 
approximately 3.4- to 67-fold higher than doses used in human clinical case reports. Notably, upon 
neurologic, clinical, and anatomic pathology examinations, no trastuzumab-related adverse effects 
occurred. CSF concentrations attained were much higher than in clinical models, as doses in this 
animal model were much higher. However, there was large variation in CSF concentrations. The 
authors attributed this variation to uneven distribution of drug throughout the CNS and rapid 
transfer of trastuzumab from the CSF into the serum after intrathecal administration. In addition 
to these animal studies, there are a limited number of reports in which intrathecal trastuzumab was 
utilized in humans (Table 110–18). 
 
The use of intrathecal trastuzumab has been described in 8 case reports involving patients with 
leptomeningeal carcinomatosis following HER2-overexpressing metastatic breast cancer.10–17 
Patients were administered intrathecal trastuzumab as salvage therapy after failing extensive 
treatment with either neurosurgery, systemic chemotherapy, intrathecal chemotherapy, or whole-
brain radiation; in many, a combination of the 4 was utilized. Intrathecal trastuzumab was used as 
monotherapy in 4 cases and given concurrently with intrathecal methotrexate or intrathecal 
thiotepa in the other 4. Doses of trastuzumab ranged from 5 to 100 mg and were repeated after as 
little as 3 days in 1 report to as long as 3 weeks in others.10,12–14 The most common schedule was 
20–30 mg weekly. All doses, including doses up to 100 mg, and schedules were well tolerated. In 
fact, an autopsy failed to reveal any toxicity, including arachnoiditis, in 1 case report.11 
Intrathecal therapy with trastuzumab resulted in noticeable relief of clinical symptoms (overflow 
incontinence, paraparesis of the legs, mental status changes, headaches, ataxia, and visual 
impairment) for 7 of the 8 patients. Two patients showed a decrease or disappearance of brain 
lesions on magnetic resonance imaging.14,17 The duration of disease control from the initiation of 
intrathecal trastuzumab ranged from 39 days to greater than 72 months, with 6 patients surviving 
greater than 5 months.12–17 Interestingly, the patient who died at day 39 of intrathecal trastuzumab 
treatment died due to progression of visceral metastases and was considered to be in remission 
with regard to the leptomeningeal carcinomatosis.10 Tumor cell counts were also found to be 
eliminated or substantially decreased in 4 of 5 patients.10,13,14,17 
In 2 reports, response appeared to be related to dose.14,15 In 1 of these, the patient was started on 
20 mg weekly and benefits from intrathecal trastuzumab were not appreciated until doses were 
increased past 30 mg.14 Intrathecal trastuzumab was coadministered with intrathecal thiotepa and 
the greatest response occurred when both trastuzumab and thiotepa doses were increased to 50 and 
12 mg, respectively. A second report also suggests that trastuzumab at doses higher than 20–30 
mg may result in increased efficacy.15 These cases, as well as other preclinical data, hint at a dose-
response relationship and the possibility of a synergistic relationship with trastuzumab and 
thiotepa.19 
Two patients had CSF concentrations of trastuzumab measured prior to dose administration. 
Intrathecal therapy showed a substantial increase in CSF concentrations of trastuzumab compared 
with systemic therapy alone. Measured CSF concentrations after intrathecal trastuzumab peaked 
at 3460 and 6425 ng/mL during therapy.10,13 Although CSF concentrations were higher than those 
seen with systemically administered trastuzumab, concentrations were still lower than serum 
concentrations (34,274 and 82,303 ng/mL, respectively). Both reports utilized a maximum dose of 
20 mg and, given the lack of toxicity (even at 100 mg) and relatively low CSF concentrations, 
higher doses may be reasonable. It is also important to remember that the 2 CSF concentrations 
described above were obtained 4 and 3 days after the dose, respectively, prior to the next dose. 
Recently, results of a small pilot study utilizing intrathecal trastuzumab have been reported in 
abstract form.18 Sixteen patients (11 with glioblastoma multiforme, 4 with breast cancer, and 1 
with medulloblastoma) were treated with 4 treatments of intrathecal trastuzumab 20–60 mg either 
weekly or every other week. Responders and those with stable disease continued therapy every 
other week indefinitely or until neurologic progression. Ten patients responded (7 with 
glioblastoma multiforme, 2 with breast cancer, 1 with medulloblastoma), with response durations 
lasting from 4 to more than 14 weeks. Despite the relatively small sample size and heterogeneous 
patient population, over 60% of the patients receiving intrathecal trastuzumab responded, with 2 
of the 4 patients with breast cancer responding. At the time this abstract was presented, patients 
continued to respond, making response duration difficult to determine from this analysis. Final 
results are necessary in order to determine trastuzumab's full effect in this study. 
Based on this pilot study and the reviewed case reports, intrathecal trastuzumab appears to be a 
promising therapy. Its use led to survivals ranging from 4 weeks to more than 72 months, and most 
patients had resolution of leptomeningeal carcinomatosis symptoms. None of the reported patients 
experienced clinical toxic effects. These observed results must be interpreted with caution given 
the heterogeneity in the doses, schedules, and concomitant therapies used in the patients. Although 
it is difficult to distinguish between the effects of systemic therapies and other intrathecal therapies 
in these reports, intrathecal trastuzumab deserves further investigation in the setting of 
leptomeningeal carcinomatosis due to HER2-positive breast cancer in order to determine the 
biologically optimal dose, schedule, and place in therapy. 
Lymphoma and Intrathecal Rituximab 
Similar to the interest in intrathecal trastuzumab, the use of intrathecal rituximab for the treatment 
of CNS lymphoma and leukemia has garnered attention. The majority of B-cell non-Hodgkin's 
lymphomas and B-cell leukemias express the CD20 antigen, and systemic rituximab (anti-CD20 
monoclonal antibody) has been shown to be effective in their treatment. Rituximab has been shown 
to increase survival; however, it has not been associated with a decrease in the risk of secondary 
CNS occurrence.20,21 The lack of an effect in decreasing the risk of CNS dissemination may be due 
to the relatively low penetration of rituximab into the CNS. In fact, CSF concentrations of 
rituximab after systemic administration have shown to be only 0.1% of the serum concentrations.22 
Like trastuzumab, the activity of rituximab coupled with relatively poor CNS penetration led to 
the current interest in the intrathecal use of this agent. An animal model utilizing intrathecal 
rituximab in cynomolgus monkeys showed this intervention to be well tolerated, with no clinical 
evidence of toxicity.22 In addition to this animal model, the use of intrathecal rituximab has been 
reported in case reports, case series, and a Phase 1 trial (Table 223–32). 
 
Seven individual case reports have been published studying the use of intrathecal rituximab for 
CNS lymphoma.23–29 Doses ranged from 10 to 40 mg and were most commonly initiated at 10 mg 
and increased to the highest tolerated dose or until acceptable clinical response occurred. All 7 
patients showed response in tumor cell clearance. Cytologic responses were also accompanied 
with symptomatic improvements in 4 cases and included neurologic improvements, disappearance 
of seizures and headaches, and cognitive improvement.24,25,27,28 Only 1 report described 
progression of CNS lymphoma.26 Survival in these 7 case reports ranged from 4 months to greater 
than 3.5 years. Three of 7 patients received high-dose chemotherapy with autologous stem cell 
rescue after receiving intrathecal rituximab.23,24,29 Adverse effects reported include neuropathic 
pain, headache, cramps, back pain, and leg weakness. Infusion reactions characterized by tingling 
sensations in the extremities, transient upward gaze of eyes, nausea, chills, hypotension, and 
disorientation were reported. These reactions occurred with the 40-mg doses and did not produce 
any long-lasting sequelae. 
The results of a case series and a prospective study investigating the safety and efficacy of 
intrathecal rituximab have also been reported. In the case series (n = 6), doses were intensified 
(10–40 mg) during the course of treatment and were given as frequently as 3 times weekly.30 Final 
outcomes were described as total clearing of malignant cells in 1 patient, disease progression in 2 
patients, and minor response in 1 patient. The prospective study included 7 pediatric patients with 
B-cell acute lymphoblastic leukemia refractory to triple intrathecal therapy (methotrexate, 
cytarabine, hydrocortisone) with or without radiation.31 Patients received intrathecal rituximab 10 
mg twice weekly for 4 weeks. After 24 months, 5 patients remained in complete remission. Patients 
receiving rituximab showed no signs of neurotoxicity. Of the 13 patients studied in both reports, 
only 1 had neurologic complications.30 This patient suffered from Burkitt's lymphoma and 
experienced a severe pain attack and paraparesis. This was thought to be related to a high tumor 
burden and rapid tumor cell lysis. Another patient experienced nausea/chills with a 40-mg dose 
immediately after administration. Survival in both reports ranged from 2 months to more than 24 
months. Similar to the small study with trastuzumab, it is difficult to determine the drug's true 
potential from these studies. Given the studies' small size, along with the differing doses and 
administration schedules, more data are necessary. However, as seen in both the case reports and 
the case series, it appears that doses of 40 mg may increase the likelihood of adverse effects. 
Intrathecal rituximab has been investigated in a Phase 1 study that sought to define its safety, 
pharmacokinetics, and efficacy.32 Doses of 10–50 mg were administered to 10 patients. Rituximab 
was administered over 1–5 minutes either diluted with NaCl 0.9% or as undiluted stock solution. 
Prior to administration, patients received acetaminophen, diphenhydramine, and famotidine or 
cimetidine and had 5 mL of CSF removed. None of the 8 patients receiving 10 and 25 mg exhibited 
signs of major toxicity. Both patients receiving 50 mg suffered from toxicities (hypertension, 
diplopia, nausea/vomiting, chest pain, and tachypnea). Symptoms resolved within 20 minutes with 
medical management. Overall, 6 patients had cytologic responses, 4 of whom had complete 
responses. The longest cytologic response was 9 montths, while survival ranged from 1.1 week to 
more than 134 weeks. Mean 1-hour postdose CSF concentrations were 214 μg/mL with the 10-mg 
dose and 472 μg/mL with the maximum tolerated dose of 25 mg. These concentrations are similar 
to peak concentrations in the serum after intravenous injection of rituximab. Concentrations 
rapidly declined after the dose, with a half life of 34.9 hours at the 25-mg dose. This rapid decline 
in concentrations was also observed in 1 of the case reports.26 As demonstrated previously with 
systemic rituximab for lymphoma, response may correlate with sustained rituximab 
concentrations.26 This Phase 1 study, along with the aforementioned small studies and 7 case 
reports, has revealed the potential of intrathecal rituximab. Although toxicities have been 
described, the majority have been with doses of 40 mg or greater and have been manageable. 
Similar to trastuzumab, additional data are necessary to determine the biologically optimal dose 
and schedule. Administration of doses more frequently may help mitigate the rapid removal of 
drug from the CSF; however, this schedule requires validation in a clinical trial. 
Practical Considerations 
It is important to use sterile water when preparing trastuzumab for intrathecal administration and 
not the provided diluent (bacteriostatic water) to prevent the intrathecal administration of 
preservative, which can lead to neurotoxicity or anaphylaxis.33 Tonicity of the drug diluted in water 
was not an issue in the described case reports. Given the lack of the preservative and the route of 
administration, trastuzumab for intrathecal use should be administered immediately after 
preparation despite the reported physical and chemical stability of 48 hours under refrigerated 
conditions and 24 hours at room temperature when prepared with sterile water.34 One case report 
gave details regarding the preparation, in which 150 mg of trastuzumab (trastuzumab is available 
in 150-mg vials in the UK and Australia) was diluted with 7.2 mL of sterile water.10 Rituximab 
was prepared in the Phase 1 trial by diluting the stock solution with preservativefree NaCl 0.9% in 
a 1:1 ratio for the 10- and 25-mg dosages or without dilution for the 50-mg dosage.32 All rituximab 
doses were administered slowly over a period of 1–5 minutes. Intrathecal trastuzumab and 
rituximab were delivered by either lumbar puncture or via an Ommaya reservoir in these reports. 
It is unknown whether the delivery method would influence outcome; however, administration of 
intrathecal agents via an Ommaya reservoir compared to repeated lumbar punctures may be 
safer.35,36 
Summary 
The prognosis for leptomeningeal carcinomatosis is quite grim with conventional therapies. 
Available options are limited to supportive care, radiation, or intrathecal chemotherapy. Additional 
options, such as steroids and systemic chemotherapy with high-dose methotrexate, are available 
for lymphomatous carcinomatosis. With the poor efficacy of these therapies and the frequency of 
leptomeningeal carcinomatosis diagnosis increasing, oncologists have challenging decisions to 
make. The blood-brain and blood-cerebrospinal barriers are believed to be the prime culprits 
preventing the accumulation of drug at the site of leptomeningeal carcinomatosis. Consequently, 
while intravenous trastuzumab and rituximab are first-line agents for their respective disease states, 
their efficacy is poor in leptomeningeal carcinomatosis, as they are unable to penetrate these 
barriers. These large monoclonal antibodies require additional assistance to reach the site of 
leptomeningeal carcinomatosis. One way is to deliver them directly into the site of CNS disease 
via intrathecal administration. The available data suggest that intrathecal trastuzumab and 
rituximab may be safe and effective and mitigate the poor penetration associated with systemic 
administration. Both agents have resulted in long periods free from disease-related symptoms that 
may impact quality of life. 
Trastuzumab was tolerated at doses ranging from 5 to 100 mg. CSF concentrations were 
determined with the 20-mg dose and found to be higher than with systemic therapy alone; however, 
CSF concentrations were lower than serum concentrations obtained with systemic therapy. 
Whether higher doses would yield higher CSF concentrations is unknown at this time and needs 
to be addressed in the setting of a Phase 1 trial. At this time, based on the available data, no 
recommendations can be made regarding a standard dose.  
Rituximab was tolerated at doses ranging from 10 to 30 mg. CSF concentrations in the Phase 1 
trial were similar to those obtained in the serum with systemic therapy. Contrary to the available 
data with trastuzumab, rituximab dose escalation above 30 mg resulted in adverse effects. At this 
time, more data are necessary to determine intrathecal rituximab's place in therapy; however, if the 
drug is utilized, a dose of 25 mg would be reasonable based on the Phase 1 data. In patients with 
a very large CNS tumor burden, dose escalation (starting with 10 mg and increasing to 25 mg) 
may be considered to prevent adverse effects from tumor lysis.  
Intrathecal therapy shows promise but is still in its infancy. The reports discussed above illustrate 
the feasibility of intrathecal administration of rituximab and trastuzumab and encourage further 
investigation. Larger studies are needed to determine biologically optimal doses, frequency, and 
duration of therapy. A patient refractory to other available treatments may benefit from intrathecal 
trastuzumab or rituximab; however, this approach remains investigational until more data are 
available.  
Article Notes 
Conflict of Interest: Authors reported none 
References 
1. National Comprehensive Cancer Network. Central nervous system cancers. v. 3. 2009. 
www.nccn.org/professionals/physician_gls/PDF/cns.pdf (accessed 2010 Feb 1). 
2. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999;25:103–19. DOI 
10.1053/crv.1999.0119. 
3. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases 
from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452–9. DOI 10.1158/1078-0432.CCR-08-
1080. 
4. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human 
epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993–9. DOI 
10.1200/JCO.2007.3588. 
5. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous 
system metastases. J Clin Oncol 2009; 27:5278–86. DOI 10.1200/JCO.2008.19.8481. 
6. Pestalozzi BC, Brignoli S. Trastuzumab in CSF (letter). J Clin Oncol 2000;18:2349–51. 
7. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels 
in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases 
and impairment of blood-brain barrier. Anticancer Drugs 2007;18:23–8. DOI 
10.1097/01.cad.0000236313.50833.ee. 
8. Grossi PM, Ochiai H, Archer GE, et al. Efficacy of intrathecal microinfusion of trastuzumab in an athymic 
rat model of intracerebral metastatic breast cancer. Clin Cancer Res 2003;9:5514–20. 
9. Braen AP, Perron J, Tellier P, Catala AR, Kolaitis G, Geng W. A 4-week intrathecal toxicity and 
pharamcokinetic study with trastuzumab in cynomolgus monkeys. Int J Toxicol 2010;29:259–67. DOI 
10.1177/1091581810361527. 
10. Stemmler HJ, Mengele K, Schmitt M, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for 
meningeal carcinomatosis in HER2-overexpressing metastastic breast cancer: A case report. Anticancer 
Drugs 2008;19:832–6. DOI 10.1097/CAD.0b013e32830b58b0. 
11. Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis 
(letter). Clin Breast Cancer 2001;2:235. 
12. Colozza M, Minenza E, Gori S, et al. Extended survival of a HER-2-positive metastatic breast cancer 
patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 
2009;63: 1157–9. DOI 10.1007/s00280-008-0859-7. 
13. Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Herceptin) for 
treatment of meningeal carcinomatosis in HER2-overexpressing metastastic breast cancer. Oncol Rep 
2006;15:1373–7. 
14. Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC. Intrathecal trastuzumab and thiotepa for 
leptomeningeal spread of breast cancer (letter). Ann Oncol 2009;20:792–5. DOI 10.1093/annonc/mdp019. 
15. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for 
leptomeningeal metastases secondary to HER-2 overexpressing breast cancer (letter). Ann Oncol 
2008;19:1978–80. DOI 10.1093/annonc/mdn654. 
16. Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal 
trastuzumab. Lancet Oncol 2006;7:778–80. DOI 10.1016/SI1470–2045(06)70864–6. 
17. Shojima K, Suzuki E, Saito K, et al. Application of intrathecal trastuzumab for treatment of meningeal 
carcinomatosis in HER2-overexpressing metastastic breast cancer (abstract 1138). J Clin Oncol 
2008;26:75S. 
18. Allison DL, Glantz M, Werner TL, Kirkegaard SL, Murdock K, Jensen R. Intra-CSF trastuzumab in 
patients with neoplastic meningitis from breast cancer or primary brain tumors (abstract 2066). J Clin 
Oncol 2009;27:15S. 
19. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and 
chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241–51. 
20. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurence in 
elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab. Ann Oncol 2004;15:129–33. 
DOI 10.1093/annonc/mdh013. 
21. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in 
elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–42. 
22. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: Targeting the 
leptomeningeal compartment. Blood 2003; 101:466–8. DOI 10.1182/blood-2002-06-1636. 
23. Villela L, Garcia M, Caballero R, Borbolla-Escoboza JR, Bolanos-Meade J. Rapid complete response using 
intrathecal rituzimab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma. 
Anticancer Drugs 2008;19:917–20. DOI 10.1097/CAD.0b013e32830cebc1. 
24. Antonini G, Cox MC, Montefusco E, et al. Intrathecal anti-CD20 antibody: An effective and safe treatment 
for leptomeningeal lymphoma. J Neurooncol 2007;81:197–9. DOI 10.1007/s11060-006-9217-y. 
25. van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J. Intrathecal rituximab treatment 
for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood 
Cancer 2008;50:886–8. DOI 10.1002/pbc.21297. 
26. Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a 
patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002;59:213–6. DOI 
10.1023/A:1019999830455. 
27. Liu CY, Teng HW, Lirng JF, Chiou TJ, Chen PM, Hsiao LT. Sustained remission and long-term survival of 
secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment 
of systemic high-dose chemotherapy and intrathecal rituximab (letter). Leuk Lymphoma 2008;49:2018–21. 
DOI 10.1080/10428190802311375. 
28. Akyuz C, Aydin G Burca, Cila A, et al. Successful use of intraventricular and intravenous rituximab 
therapy for refractory primary CNS lymphoma in a child (letter). Leuk Lymphoma 2007;48:1253–5. DOI 
10.1080/10428190601142831. 
29. Hong SJ, Kim JS, Chang JH, et al. A successful treatment of relapsed primary CNS lymphoma patient with 
intraventricular rituximab followed by high dose chemotherapy with autologous stem cell rescue. Yonsei 
Med J 2009;50:280–3. DOI 10.3349/ymj.2009.50.2.280. 
30. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed 
central nervous system lymphoma with anti-CD20 antibody rituximab (letter). Haematologica 
2004;89:753–4. 
31. Jaime-Perez JC, Rodriguez-Romo LN, Gonzalez-Llano O, Chapa-Rodriguez A, Gomez-Almaguer D. 
Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukemia relapsed to the CNS 
and resistant to conventional therapy (letter). Br J Haematol 2008;144:794–805. DOI 10.1111/j.1365–
2141.2008.07497.x. 
32. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in 
patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350–6. DOI 
10.1200/JCO.2006.09.7311. 
33. Siderov J. Care with intrathecal trastuzumab (letter). Lancet Oncol 2006; 7:888. 
34. Electronic medicines compendium. 
http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc.asp&documentid=3567 (accessed 
2010 Jun 9). 
35. Blaney SM, Poplock DG, Godwin K, McCully CL, Murphy R, Balis FM. Effect of body position on 
ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol 
1995;13:177–9. 
36. Shapiro WR, Young DF, Mehta BM. Methotrexate: Distribution in cerebrospinal fluid after intravenous, 
ventricular and lumbar injections. N Engl J Med 1975;293:161–6. 
